Loading
A phase 3 trial testing QLS31905 in pancreatic ductal adenocarcinoma, now recruiting.
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer is a phase 3 interventional study registered as NCT07079228, led by Qilu Pharmaceutical, and recruiting on the registry. Official title: A Phase 3, Multi-Center, Double-blind, Randomised Study of QLS31905 Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-Line Treatment in Participants With Claudin (CLDN)18.2-Positive Advanced Pancreatic Cancer. Planned enrolment is 602 participants (estimated). The study started in 2025-09-08 and primary completion is expected in 2028-12. No results have been posted on ClinicalTrials.gov.